{rfName}
St

Licencia y uso

Icono OpenAccess

Citaciones

1

Altmetrics

Análisis de autorías institucional

Usandizaga Elio, RamonAutor o CoautorFrías Iniesta, JesúsAutor o Coautor

Compartir

14 de marzo de 2019
Publicaciones
>
Artículo

Study on the conditions of use for Caribán® and other antiemetics in the treatment of nausea and vomiting during pregnancy

Publicado en:Progresos en Obstetricia y Ginecologia. 61 (5): 449,457-455 - 2018-09-01 61(5), DOI: 10.20960/j.pog.00130

Autores: Usandizaga Elio, Ramón; Meler Barrabés, Eva; Frías, L; Serrano Olmedo, Ariana; Martínez Ávila, José Carlos; Frías Iniesta, Jesús

Afiliaciones

Resumen

© 2018, Sociedad Espanola de Ginecologia y Obstetricia. All rights reserved. Objective: We performed a prospective observational study on the conditions of use of a medication, Caribán®, and of other antiemetics for the treatment of nausea and vomiting in pregnancy. The study was practical in design, and its main objective was to determine the frequency of use of Caribán® in the treatment of nausea and vomiting in pregnancy by analyzing conditions of use in daily clinical practice. Material and methods: The study population comprised 184 pregnant women with nausea and/or vomiting during the days preceding the first study visit. The patients attended up to 4 visits, 3 of which were face-to-face, and provided clinical follow-up data and data on the treatment used by means of an app. Data on treatment and the evaluation of nausea and vomiting were obtained every 24 hours using the Pregnancy-Unique Quantification of Emesis and Nausea score. Results: The most frequently used initial regimen was 1 capsule every 8 hours. Data were available from the baseline visit and from the daily follow-up of 158 women (ie, 4,982 daily evaluations). The mean score for severity of nausea and vomiting in pregnancy was 5.69 points (mild) (SD, 1.8; range, 3-13) and the mean cumulative dose per woman throughout the follow-up was 34.61 capsules (6-197). Nausea and vomiting in pregnancy was mild in 72.48% of evaluations, moderate in 26.57%, and severe in 0.94%. Patients did not take medication in 54% (n=1969) of the mild daily episodes and in 14% of the moderate episodes. Mean consumption per daily episode was 1.74 (0-10) capsules per episode of mild nausea and vomiting in pregnancy and 2.14 (0-35) capsules per episode of moderate nausea and vomiting in pregnancy. Women who had nausea and vomiting in pregnancy took Caribán® according to the app on 66.7% of the days with symptoms. Conclusions: The most common initial regimen prescribed was 1 capsule every 8 hours. Most of the episodes of nausea and vomiting in pregnancy were mild, and on 50.85% of days with mild nausea and vomiting in pregnancy, the women did not take medication. The mean daily dose per mild episode was 1.74 capsules. The patients reported having taken medication for moderate nausea and vomiting in pregnancy in 86% of cases. The mean dose per episode was 2.14 capsules. The patients took Caribán® on 66.7% of days with nausea and vomiting in pregnancy.

Palabras clave

AntiemeticsCaribán®Doxylamine-pyridoxamineDrug use studyNausea and vomiting in pregnancy

Indicios de calidad

Impacto bibliométrico. Análisis de la aportación y canal de difusión

2025-08-02:

  • Scopus: 1

Impacto y visibilidad social

Desde la dimensión de Influencia o adopción social, y tomando como base las métricas asociadas a las menciones e interacciones proporcionadas por agencias especializadas en el cálculo de las denominadas “Métricas Alternativas o Sociales”, podemos destacar a fecha 2025-08-02:

  • La utilización de esta aportación en marcadores, bifurcaciones de código, añadidos a listas de favoritos para una lectura recurrente, así como visualizaciones generales, indica que alguien está usando la publicación como base de su trabajo actual. Esto puede ser un indicador destacado de futuras citas más formales y académicas. Tal afirmación es avalada por el resultado del indicador “Capture” que arroja un total de: 5 (PlumX).

Es fundamental presentar evidencias que respalden la plena alineación con los principios y directrices institucionales en torno a la Ciencia Abierta y la Conservación y Difusión del Patrimonio Intelectual. Un claro ejemplo de ello es:

  • El trabajo se ha enviado a una revista cuya política editorial permite la publicación en abierto Open Access.

Análisis de liderazgo de los autores institucionales

Existe un liderazgo significativo ya que algunos de los autores pertenecientes a la institución aparecen como primer o último firmante, se puede apreciar en el detalle: Primer Autor (USANDIZAGA ELIO, RAMON) y Último Autor (FRIAS INIESTA, JESUS A.).